Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crescent Biopharma closed its underwritten public offering of 9.4M ordinary shares and pre-funded warrants, generating gross proceeds of approximately $143.7 million. The offering included the full exercise of the underwriters' option to purchase additional shares.
Key figures
- Deal Value Usd
- $143.7 million
- Offering Price
- 14.5
- Shares Offered
- 9387896
- Prefunded warrants
- 525897
- Prefunded warrant price
- 14.499
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.